BioCardia, Inc.: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Apr 9, 2020 and accepted by EDGAR at Apr 9, 2020, 13:54 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2019-01-01 to 2019-12-31 | $710.0k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 12 months2019-01-01 to 2019-12-31 | $358.0k | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months2019-01-01 to 2019-12-31 | $8.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2019-01-01 to 2019-12-31 | $6.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$14.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2019-01-01 to 2019-12-31 | $112.0k | us-gaap:InterestExpense |
| Income tax | 12 months2019-01-01 to 2019-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$14.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | −$2.61 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | −$9.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $146.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-12-31 | $5.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $6.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $7.7m | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $4.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $5.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-12-31 | $2.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-20-007405. Last ingested by Listed: Nov 10, 2026, 21:12 ET. Listed shows no prices and gives no investment advice.